Amylyx Pharmaceuticals (AMLX) Liabilities and Shareholders Equity (2021 - 2026)

Amylyx Pharmaceuticals' Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $293.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 33.65% year-over-year to $293.6 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 18.81% YoY), while the FY2025 annual figure was $332.6 million, up 71.79% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $293.6 million, down from $332.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $517.5 million in Q4 2023, with the low at $181.4 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $332.2 million (2024), against an average of $324.4 million.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 270.64% in 2022, then tumbled 62.58% in 2024.
• Amylyx Pharmaceuticals' Liabilities and Shareholders Equity stood at $391.5 million in 2022, then soared by 32.19% to $517.5 million in 2023, then sank by 62.58% to $193.6 million in 2024, then surged by 71.79% to $332.6 million in 2025, then declined by 11.74% to $293.6 million in 2026.
• Business Quant data shows AMLX's Liabilities and Shareholders Equity at $293.6 million in Q1 2026, $332.6 million in Q4 2025, and $362.7 million in Q3 2025.